Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Average Rating of “Moderate Buy” from Analysts

Satellos Bioscience Inc. (NASDAQ:MSLE) has received an average recommendation of “Moderate Buy” from the seven brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $18.00.

A number of research analysts recently commented on MSLE shares. Cantor Fitzgerald assumed coverage on shares of Satellos Bioscience in a report on Wednesday, March 11th. They issued an “overweight” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Monday, May 11th. Guggenheim initiated coverage on Satellos Bioscience in a research report on Tuesday, April 28th. They set a “buy” rating and a $23.00 price objective on the stock. Canaccord Genuity Group raised Satellos Bioscience to a “moderate buy” rating in a research note on Thursday, May 21st. Finally, Wall Street Zen upgraded Satellos Bioscience from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th.

Satellos Bioscience Stock Performance

Satellos Bioscience stock opened at $6.75 on Tuesday. The stock has a market capitalization of $140.60 million, a P/E ratio of -4.22 and a beta of 1.60. The company’s fifty day simple moving average is $7.08. Satellos Bioscience has a 52-week low of $4.53 and a 52-week high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). As a group, sell-side analysts anticipate that Satellos Bioscience will post -2.26 EPS for the current year.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.